 | • レポートコード：B-MOR-05182 • 出版社/出版日：Mordor Intelligence / 2018年4月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、子宮内膜がんの世界市場について調べ、子宮内膜がんの世界規模、市場動向、市場環境、がんの種類別分析、治療別分析、診断方法別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・子宮内膜がんの世界市場インサイト ・子宮内膜がんの世界市場環境 ・子宮内膜がんの世界市場動向 ・子宮内膜がんの世界市場規模 ・子宮内膜がんの世界市場規模：がんの種類別 ・子宮内膜がんの世界市場規模：治療別 ・子宮内膜がんの世界市場規模：診断方法別 ・子宮内膜がんの世界市場：地域別市場規模・分析 ・子宮内膜がんの北米市場規模・予測 ・子宮内膜がんのアメリカ市場規模・予測 ・子宮内膜がんのヨーロッパ市場規模・予測 ・子宮内膜がんのアジア市場規模・予測 ・子宮内膜がんの日本市場規模・予測 ・子宮内膜がんの中国市場規模・予測 ・子宮内膜がんのインド市場規模・予測 ・子宮内膜がんの韓国市場規模・予測 ・関連企業情報・競争状況 |
The Endometrial Cancer Market is expected to witness a lucrative growth during the forecast period. Endometrial cancer is the malignancy that develops in the layers of the cells that forms the endometrium, lining of uterus. Women with high blood pressure, diabetes, or breast cancer are at a greater risk of being affected with endometrial cancer. According to the American Cancer Society, in 2017, about 61,380 new cases of uterus body cancer have been diagnosed, and about 10,920 women died due to the uterine cancer. This market is likely to witness a significant growth, leading to an increase in the opportunity for the drug manufacturers.
Rising of the Healthcare Expenditure
The rising healthcare expenditure among the urban population and the initiatives taken by various governments for improving their healthcare infrastructure, is fueling the global endometrial cancer market. The presence of the equitable, responsive, and efficient health systems present across the countries in North America, Europe, and the Asia-Pacific has contributed to the maximum share of the GDP being utilized as healthcare expenditure. The US healthcare expenditure has grown by 5.8% in 2015, amounting to USD 3.03 trillion or USD 9,451 per person. Norway and Switzerland are the next big spenders on health per capita. Some of the other countries with maximum healthcare spending includes Germany, Canada, and the Netherlands, among others. The above given statistics shows that the overall expenditure for healthcare is on a rise in many of the countries, thus driving the market for endometrial cancer.
The other factors driving the market for the endometrial cancer include rise in awareness of uterine diseases and their available therapies, innovation in drug development, and growth of diagnostic tests.
Adverse Side-effects of Treatment
There are various side effects of cancer therapy, and the endometrial cancer, on its own, can produce symptoms such as the vaginal bleeding, pain during intercourse, and persistent pain in the lower abdomen or the pelvic area. Also, there are side-effects caused by these therapies which includes fever, fullness due to fluid in the abdomen, anemia, swelling caused by lymphedema, blood clots, difficulty urinating or constipation, and shortening of the vagina. The radiation therapy also has several side-effects, such as fatigue, dryness, itching, tightening, and burning in the vagina. These short-term side-effects are restraining the endometrial cancer market.
The other factors restricting the endometrial cancer market are low success rate in clinical trials for cancer drugs and high-costs associated with the treatment.
North America Dominates the Market
North America holds the major market, owing to the large number of research and development activities, along with high healthcare expenditure. In the United States, endometrial cancer is the most common type cancer of the female reproductive system and is the fourth most common cancer among women. Europe is expected to hold the second largest share in the global market, due to the growing product availability in the regions.
Key Developments in the Market
• January 2018: Eisai and Merck receive a breakthrough therapy designation from FDA for LENVIMA (lenvatinib mesylate) and KEYTRUDA (pembrolizumab) as a combination therapy for the advanced and/or metastatic renal cell carcinoma.
Major Players: ARIAD PHARMACEUTICALS, ABBOTT LABORATORIES, BECTON DICKINSON & CO., GLAXOSMITHKLINE, MERCK, NOVARTIS AG, SANOFI, SIEMENS HEALTHCARE, AND ROCHE, amongst others.
Reasons to Purchase this Report
• Current and future global Endometrial Cancer Market outlook in the developed and emerging markets
• Various perspectives of the market, with the help of Porter’s five forces analysis
• The segment expected to dominate the market
• The region expected to witness the fastest growth rate during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rise in Awareness about Uterine Diseases and Their Available Therapies
6.1.2 Increasing Health Care Expenditure
6.1.3 Innovation in Drug Development, and Subsequent Technological Advancements
6.1.4 Growing of the Diagnostic Tests
6.2 Market Restraints
6.2.1 Low Success Rate in Clinical Trials for Cancer Drugs
6.2.2 High-Cost Associated with the Treatment
6.2.3 Adverse Side-Effects of Treatment and High Toxicity of Drugs
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type of Cancer
7.1.1 Endometrial Carcinoma
7.1.1.1 Adenocarcinoma
7.1.1.2 Carcinosarcoma
7.1.1.3 Squamous Cell Carcinoma
7.1.1.4 Others
7.1.2 Uterine sarcomas
7.2 By Type of Therapy
7.2.1 Surgery
7.2.2 Immunotherapy
7.2.3 Radiation Therapy
7.2.4 Chemotherapy
7.2.4.1 Paclitaxel (Taxol)
7.2.4.2 Carboplatin
7.2.4.3 Doxorubicin (Adriamycin) or Liposomal Doxorubicin (Doxil)
7.2.4.4 Cisplatin
7.2.4.5 Others
7.2.5 Follow-Up Treatment
7.2.6 Others
7.3 By Diagnosis Method
7.3.1 Biopsy
7.3.2 Pelvic Ultrasound
7.3.3 Hysteroscopy
7.3.4 Dilation and Curettage
7.3.5 CT Scan
7.3.6 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Ariad Pharmaceuticals
9.2 Abbott Laboratories
9.3 Becton, Dickinson & Co.
9.4 GlaxoSmithKline
9.5 Merck
9.6 Novartis AG
9.7 Sanofi
9.8 Siemens Healthcare
9.9 Roche
9.10 List Not Exhaustive
10. Future of the Market